Formycon AG (FYB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Formycon AG (FYB) has a cash flow conversion efficiency ratio of 0.011x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€4.54 Million ≈ $5.30 Million USD) by net assets (€399.14 Million ≈ $466.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Formycon AG worth for the company's overall valuation and market capitalisation.
Formycon AG - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Formycon AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Formycon AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formycon AG ranked by their cash flow conversion efficiency. Explore cash flow quality index of Formycon AG to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Xinri E-Vehicle Co Ltd
SHG:603787
|
0.161x |
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
0.063x |
|
Shanghai Challenge Textile Co Ltd
SHE:002486
|
0.068x |
|
Marie Brizard Wine & Spirits
PA:MBWS
|
0.019x |
|
BP p.l.c
LSE:BP-A
|
0.103x |
|
JSL S.A
SA:JSLG3
|
0.426x |
|
Wildcat Resources Ltd
AU:WC8
|
-0.002x |
|
Nanjing Chixia Development Co Ltd
SHG:600533
|
0.003x |
Annual Cash Flow Conversion Efficiency for Formycon AG (2009–2025)
The table below shows the annual cash flow conversion efficiency of Formycon AG from 2009 to 2025. View FYB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €399.14 Million ≈ $466.63 Million |
€10.78 Million ≈ $12.61 Million |
0.027x | +153.73% |
| 2024-12-31 | €461.84 Million ≈ $539.94 Million |
€-23.22 Million ≈ $-27.15 Million |
-0.050x | -156.68% |
| 2023-12-31 | €502.75 Million ≈ $587.77 Million |
€-9.85 Million ≈ $-11.51 Million |
-0.020x | +63.23% |
| 2022-12-31 | €356.58 Million ≈ $416.88 Million |
€-18.99 Million ≈ $-22.21 Million |
-0.053x | +78.01% |
| 2021-12-31 | €55.89 Million ≈ $65.34 Million |
€-13.54 Million ≈ $-15.83 Million |
-0.242x | -216.50% |
| 2020-12-31 | €68.04 Million ≈ $79.54 Million |
€-5.21 Million ≈ $-6.09 Million |
-0.077x | -145.04% |
| 2019-12-31 | €48.21 Million ≈ $56.36 Million |
€-1.51 Million ≈ $-1.76 Million |
-0.031x | -107.81% |
| 2018-12-31 | €33.24 Million ≈ $38.86 Million |
€13.30 Million ≈ $15.55 Million |
0.400x | +345.01% |
| 2017-12-31 | €25.54 Million ≈ $29.86 Million |
€-4.17 Million ≈ $-4.88 Million |
-0.163x | +32.29% |
| 2016-12-31 | €20.89 Million ≈ $24.42 Million |
€-5.04 Million ≈ $-5.89 Million |
-0.241x | -1260.19% |
| 2015-12-31 | €24.87 Million ≈ $29.08 Million |
€517.00K ≈ $604.43K |
0.021x | +981.57% |
| 2014-12-31 | €13.64 Million ≈ $15.95 Million |
€-32.17K ≈ $-37.61K |
-0.002x | +99.83% |
| 2013-12-31 | €12.25 Million ≈ $14.32 Million |
€-16.65 Million ≈ $-19.47 Million |
-1.359x | -368.19% |
| 2012-12-31 | €4.26 Million ≈ $4.98 Million |
€2.16 Million ≈ $2.52 Million |
0.507x | +6644.70% |
| 2011-12-31 | €5.14 Million ≈ $6.01 Million |
€38.60K ≈ $45.13K |
0.008x | +101.07% |
| 2010-12-31 | €4.07 Million ≈ $4.76 Million |
€-2.85 Million ≈ $-3.33 Million |
-0.700x | +8.21% |
| 2009-12-31 | €640.00K ≈ $748.23K |
€-487.93K ≈ $-570.44K |
-0.762x | -- |
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more